A U.S. judge rejected Bayer’s request to block Johnson & Johnson’s advertising for the prostate cancer drug Erleada.
Bayer’s lawsuit alleged J&J falsely claimed Erleada cuts the risk of death in half compared to its rival drug, Nubeqa.
The court ruled Bayer was unlikely to succeed because J&J’s ads accurately reflected its clinical study findings.
The ruling allows J&J to continue marketing Erleada, which generated $3.57 billion in 2025 sales.